Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in CashFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Net Cash Flow (2019 - 2025)

Goldenwell Biotech's Net Cash Flow history spans 7 years, with the latest figure at -$30885.0 for Q3 2025.

  • For Q3 2025, Net Cash Flow fell 33.9% year-over-year to -$30885.0; the TTM value through Sep 2025 reached $40867.0, up 670.45%, while the annual FY2024 figure was -$3827.0, 152.9% down from the prior year.
  • Net Cash Flow reached -$30885.0 in Q3 2025 per GWLL's latest filing, down from $59380.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $59380.0 in Q2 2025 to a low of -$917090.0 in Q4 2022.
  • Average Net Cash Flow over 5 years is -$56050.7, with a median of -$12506.0 recorded in 2021.
  • Peak YoY movement for Net Cash Flow: surged 14130.99% in 2021, then crashed 4633.86% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$19373.0 in 2021, then plummeted by 4633.86% to -$917090.0 in 2022, then soared by 104.5% to $41312.0 in 2023, then increased by 8.08% to $44649.0 in 2024, then crashed by 169.17% to -$30885.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Net Cash Flow are -$30885.0 (Q3 2025), $59380.0 (Q2 2025), and -$32277.0 (Q1 2025).